About Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited is an Indian pharmaceutical company established in 1979 and incorporated in 2007. It operates as a global Contract Development and Manufacturing Organisation (CDMO) with a mission to provide simple, accessible financial services. The company’s business model is focused on contract development and manufacturing, along with the production and marketing of specialty chemicals, vitamins, and disinfectants.

The company has a global presence with manufacturing and R&D facilities across India, Switzerland, the UK, France, China, and the Netherlands. It operates 25 manufacturing facilities and 28 R&D labs worldwide. A significant milestone was the acquisition of Carbogen Amcis in 2006, which helped transform the company into a global pharmaceutical pioneer. As of March 31, 2025, the company had 18 subsidiaries.

Dishman Carbogen Amcis Limited’s Business Segments

The company’s revenue mix is divided into two main business areas:

• CDMO: This segment contributed 84.6% of the company’s turnover in FY25.
• Marketable Molecules: This segment contributed 15.4% of the turnover in FY25 and includes speciality chemicals, vitamins and analogues, generic APIs, and disinfectants.

Dishman Carbogen Amcis Limited’s Key Management

• Arpit J. Vyas – Global Managing Director
• Deohooti J. Vyas – Whole-Time Director
• Rajendra S. Shah – Independent Director
• Maitri K. Mehta – Independent Director
• Kulin N. Shah – Independent Director
• Hemantkumar J. Bhatt – Independent Director
• Dr. Margie S. Parikh – Independent Director
• Dhaval R. Shah – Non-Executive & Non-Independent Director
• Harshil Dalal – Global Chief Financial Officer
• Shrima G. Dave – Company Secretary

Latest Updates on Dishman Carbogen Amcis Limited

• Passing of the Founder: The company mourned the passing of its founder Chairman, Shri Janmejay R. Vyas, in May 2025.
• Strategic Expansion: A co-investment agreement of CHF 25 million was made with a Japanese innovator to expand ADC linker capacity in Switzerland, with full operations expected by 2027.
• Operational Milestones: The company received GMP certification for its French sterile injectables facility and a new drug manufacturing license from the Chinese regulatory body for its Shanghai site. The Bavla site also received an Establishment Inspection Report (EIR) from the US FDA, indicating the closure of the inspection.
• Financial Performance: Consolidated revenue grew from ₹2,615.8 crore in FY24 to ₹2,711.5 crore in FY25, a 3.7% increase year-on-year. The consolidated EBITDA grew to ₹468.94 crore in FY25 from ₹286.50 crore in FY24, marking a 63.7% increase.
• Leadership Changes: Stephan Fritschi has been promoted to CEO of Carbogen Amcis. Mr Hemantkumar Jayantiprasad Bhatt and Dr Margie Sunil Parikh were appointed as Independent Directors from April 1, 2025.
• Capital and Fund Infusion: The company raised around ₹2,150 crore through an IPO in May 2025, with proceeds used for debt reduction.
• Strategic Direction: The company has applied to the RBI to transition to a Universal Bank, with approval awaited.